Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

This study has been completed.
Sponsor:
Information provided by:
Bnai Zion Medical Center
ClinicalTrials.gov Identifier:
NCT00261937
First received: December 5, 2005
Last updated: February 5, 2013
Last verified: December 2005

December 5, 2005
February 5, 2013
December 2005
Not Provided
Clinical respiratory effects
Same as current
Complete list of historical versions of study NCT00261937 on ClinicalTrials.gov Archive Site
  • 1. The duration of hospitalization
  • 2. Time weaned off oxygen
  • 3. Time to full enteral feeding
Same as current
Not Provided
Not Provided
 
Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants
Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Bronchiolitis
Drug: Inhaled Furosemide vs Placebo (Normal Saline)
Not Provided
Bar A, Srugo I, Amirav I, Tzverling C, Naftali G, Kugelman A. Inhaled furosemide in hospitalized infants with viral bronchiolitis: a randomized, double-blind, placebo-controlled pilot study. Pediatr Pulmonol. 2008 Mar;43(3):261-7. doi: 10.1002/ppul.20765.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
April 2006
Not Provided

Inclusion Criteria:

  • Age: 0-12 months.
  • Infants who are otherwise healthy
  • Infants with chronic lung disease of prematurity (BPD) will be included, but will be analyzed separately.
  • Parents signed a written informed consent.

Exclusion Criteria:

  • • Other previous or co-morbidity, specifically: respiratory (other than BPD, like Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.
Both
up to 12 Months
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00261937
67/05
Not Provided
Not Provided
Bnai Zion Medical Center
Not Provided
Principal Investigator: Amir Kugelman Bnai Zion Medical Center
Bnai Zion Medical Center
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP